Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552929 | 1.00 | GRM2 (0.58) | GRM2GAAAGTR2HTR2AS1PR1 | |
| SCHEMBL5367420 | 1.00 | GRM2 (0.58) | GRM2GAAAGTR2HTR2AS1PR1 | |
| SCHEMBL11146494 | 0.86 | GRM2 (0.52) | GRM2GAAAGTR2HTR2AS1PR1 | |
| SCHEMBL5685796 | 0.83 | GRM2 (0.56) | GRM2AGTR2HTR2AMEN1KMT2A | |
| SCHEMBL5685651 | 0.83 | GRM2 (0.56) | GRM2AGTR2HTR2AMEN1KMT2A | |
| SCHEMBL5685811 | 0.83 | GRM2 (0.56) | GRM2AGTR2HTR2AMEN1KMT2A | |
| SCHEMBL5558161 | 0.82 | FKBP1A (0.48) | GRM2GAAKMT2A | |
| SCHEMBL5370163 | 0.82 | FKBP1A (0.48) | GRM2GAAKMT2A | |
| SCHEMBL5375688 | 0.82 | FKBP1A (0.48) | GRM2GAAKMT2A | |
| SCHEMBL23464974 | 0.81 | GRM6 (0.56) | AGTR2S1PR1S1PR5KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268228-B2 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO., LTD. (KR) | 2007-09-11 | — | — | US | claimed |
| EP-1309550-A4 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO LTD (KR) | 2004-07-07 | — | — | EP | claimed |
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO. LTD. (KR) | 2004-02-12 | — | — | US | claimed |
| EP-1309550-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | Chembionex Co., Ltd (KR) | 2003-05-14 | — | — | EP | claimed |
| WO-2002012186-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | claimed |
| US-7268228-B2 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO., LTD. (KR) | 2007-09-11 | — | — | US | disclosed |
| EP-1309550-A4 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO LTD (KR) | 2004-07-07 | — | — | EP | disclosed |
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO. LTD. (KR) | 2004-02-12 | — | — | US | disclosed |
| EP-1309550-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | Chembionex Co., Ltd (KR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012186-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | HRH2, HRH1, DDC | GRM2 1382/4885GAA 1763/4885AGTR2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.